Market Summary
USD293.71+0.49
Market Closed0.17%
SYK Alerts
SYK Stock Price
SYK RSI Chart
SYK Valuation
SYK Price/Sales (Trailing)
SYK Profitability
SYK Fundamentals
SYK Revenue
SYK Earnings
Price Action
52 Week Range
200.12306.93
(Low)(High)
Last 7 days
-0.4%
Last 30 days
5.7%
Last 90 days
-1.3%
Trailing 12 Months
33.0%
SYK Financial Health
SYK Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for SYK
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-06 | Menon Viju | sold | -1,445,000 | 289 | -5,000 | group president |
2023-08-10 | Datar Srikant M. | sold | -214,671 | 286 | -750 | - |
2023-08-08 | Datar Srikant M. | acquired | 186,120 | 93.06 | 2,000 | - |
2023-08-08 | Datar Srikant M. | sold (taxes) | -186,362 | 286 | -651 | - |
2023-08-01 | Fletcher Robert S | sold (taxes) | -95,792 | 283 | -338 | vp, chief legal officer |
2023-06-09 | Lobo Kevin | gifted | - | - | -8,904 | chair and ceo |
2023-06-05 | Lobo Kevin | gifted | - | - | -8,904 | chair and ceo |
2023-06-01 | Datar Srikant M. | sold | -139,250 | 278 | -500 | - |
2023-05-18 | Datar Srikant M. | sold | -286,000 | 286 | -1,000 | - |
2023-05-10 | Skeete Tatum Lisa M | acquired | - | - | 705 | - |
Which funds bought or sold SYK recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-15 | CJM Wealth Advisers, Ltd. | unchanged | - | 15,892 | 247,123 | 0.12% |
2023-09-12 | Farther Finance Advisors, LLC | added | 55.67 | 128,646 | 322,480 | 0.07% |
2023-09-11 | Dechtman Wealth Management, LLC | new | - | 360,980 | 360,980 | 0.11% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | 1,196 | 18,610 | -% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 590,349 | 590,349 | 0.03% |
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | 20.00 | 306 | -% |
2023-09-05 | Covenant Partners, LLC | added | 4.06 | 48,856 | 484,483 | 0.17% |
2023-09-01 | Manhattan West Asset Management, LLC | reduced | -15.81 | -32,401 | 290,751 | 0.11% |
2023-08-30 | Western Wealth Management, LLC | added | 1.46 | 32,986 | 424,097 | 0.04% |
2023-08-29 | EFG Asset Management (Americas) Corp. | reduced | -3.8 | 11,425 | 417,363 | 0.10% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
SYK Alerts
Schedule 13G FIlings of Stryker
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 4.0% | 14,929,245 | SC 13G/A | |
| Feb 10, 2023 | greenleaf trust | 5.3% | 19,869,434 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 7.99% | 30,246,178 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.5% | 24,494,206 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 5.5% | 21,156,776 | SC 13G/A | |
| Feb 11, 2022 | greenleaf trust | 5.4% | 20,452,972 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 7.60% | 28,652,681 | SC 13G/A | |
| Feb 07, 2022 | blackrock inc. | 6.3% | 23,860,749 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 7.9% | 29,889,060 | SC 13G/A | |
| Feb 11, 2021 | greenleaf trust | 5.6% | 21,048,539 | SC 13G/A |
Recent SEC filings of Stryker
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 04, 2023 | 10-Q | Quarterly Report | |
| Aug 03, 2023 | 8-K | Current Report | |
| Aug 03, 2023 | 4 | Insider Trading | |
| Jun 16, 2023 | 8-K | Current Report | |
| Jun 15, 2023 | 4/A | Insider Trading | |
| Jun 13, 2023 | 4 | Insider Trading |
Peers (Alternatives to Stryker)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 111.5B | 19.5B | 5.69% | 32.97% | 41.17 | 5.73 | 10.36% | 30.30% |
ISRG | 105.3B | 6.7B | 4.79% | 48.19% | 73.87 | 15.8 | 11.75% | -0.66% |
BSX | 76.7B | 13.4B | 5.66% | 28.78% | 84.09 | 5.72 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -2.82% | 6.66% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 44.4B | 5.7B | -4.65% | -17.80% | 31.95 | 7.85 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 10.1B | 937.8M | 4.57% | 35.10% | 345.61 | 10.73 | 16.30% | 250.21% |
SWAV | 7.7B | 616.6M | -5.28% | -28.68% | 31.46 | 12.45 | 69.52% | 343.68% |
GMED | 5.3B | 1.1B | -3.27% | -11.90% | 25.4 | 4.87 | 12.63% | 50.85% |
IRTC | 2.9B | 452.1M | -15.03% | -38.95% | -28.79 | 6.32 | 24.99% | 24.09% |
TNDM | 1.4B | 790.3M | -24.48% | -59.71% | -6.39 | 1.81 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -7.15% | 55.58% | -9.77 | 3.87 | 44.49% | -2.43% |
AVNS | 959.6M | 780.7M | -7.16% | -11.41% | -26.66 | 1.23 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 637.3M | 162.9M | -22.73% | -61.80% | -12.05 | 3.91 | 42.67% | 12.82% |
Stryker News
Returns for SYK
Cumulative Returns on SYK
16.5%
10-Year Cumulative Returns
15.5%
7-Year Cumulative Returns
12.1%
5-Year Cumulative Returns
13.3%
3-Year Cumulative Returns
Risks for SYK
What is the probability of a big loss on SYK?
36.9%
Probability that Stryker stock will be more than 20% underwater in next one year
18.5%
Probability that Stryker stock will be more than 30% underwater in next one year.
0%
Probability that Stryker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SYK drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Stryker was unfortunately bought at previous high price.
Drawdowns
Financials for Stryker
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 2.7% | 19,455 | 18,952 | 18,449 | 17,948 | 17,629 | 17,430 | 17,108 | 16,669 | 16,246 | 14,716 | 14,351 | 14,220 | 14,070 | 14,956 | 14,884 | 14,549 | 14,204 | 13,876 | 13,601 | 13,276 | 13,040 |
| Gross Profit | 3.0% | 12,215 | 11,860 | 11,578 | 11,387 | 11,247 | 11,193 | 10,968 | 10,640 | 10,459 | 9,235 | 9,057 | 9,043 | 8,912 | 9,744 | 9,696 | 9,449 | 9,274 | 9,084 | 8,938 | 8,723 | 8,552 |
| Operating Expenses | 1.9% | 8,893 | 8,731 | 8,737 | 8,541 | 8,635 | 8,621 | 8,384 | 8,126 | 7,660 | 7,188 | 6,834 | 6,625 | 6,725 | 6,924 | 6,983 | 6,982 | 6,859 | 6,610 | 6,401 | 6,170 | 6,050 |
| S&GA Expenses | 2.6% | 6,693 | 6,526 | 6,455 | 6,449 | 6,596 | 6,562 | 6,427 | 6,244 | 5,886 | 5,606 | 5,361 | 5,179 | 5,226 | 5,283 | 5,356 | 5,407 | 5,358 | 5,266 | 5,099 | 4,885 | 4,746 |
| R&D Expenses | -0.4% | 1,375 | 1,380 | 1,454 | 1,459 | 1,401 | 1,360 | 1,235 | 1,159 | 1,095 | 1,018 | 984 | 983 | 987 | 1,000 | 971 | 938 | 913 | 883 | 862 | 846 | 823 |
| EBITDA | -100.0% | - | 3,675 | 3,378 | - | 2,727 | 2,993 | 2,977 | - | - | 2,546 | 2,769 | 3,016 | 2,817 | 3,469 | 3,359 | 3,042 | 2,995 | 3,053 | 3,115 | 3,090 | 3,027 |
| EBITDA Margin | -100.0% | - | 0.19* | 0.18* | - | 0.15* | 0.17* | 0.17* | - | - | 0.17* | 0.19* | 0.21* | 0.20* | 0.23* | 0.23* | 0.21* | 0.21* | 0.22* | 0.23* | 0.23* | 0.23* |
| Interest Expenses | - | - | - | 324 | - | - | - | 325 | - | - | - | 304 | - | - | - | 286 | - | - | - | 248 | - | - |
| Earnings Before Taxes | 6.0% | 3,155 | 2,976 | 2,683 | 2,679 | 2,358 | 2,300 | 2,281 | 2,195 | 2,480 | 1,731 | 1,954 | 2,219 | 2,020 | 2,672 | 2,562 | 2,283 | 2,236 | 2,294 | 2,356 | 2,348 | 2,285 |
| EBT Margin | -100.0% | - | 0.16* | 0.15* | 0.15* | 0.13* | 0.13* | 0.13* | 0.13* | 0.15* | 0.12* | 0.14* | 0.16* | 0.14* | 0.18* | 0.17* | 0.16* | 0.16* | 0.17* | 0.17* | 0.18* | 0.18* |
| Net Income | 3.1% | 2,709 | 2,627 | 2,358 | 2,457 | 2,079 | 2,015 | 1,994 | 1,900 | 2,083 | 1,408 | 1,599 | 1,756 | 1,601 | 2,164 | 2,083 | 3,426 | 3,550 | 3,522 | 3,553 | 1,236 | 1,080 |
| Net Income Margin | -100.0% | - | 0.14* | 0.13* | 0.14* | 0.12* | 0.12* | 0.12* | 0.11* | 0.13* | 0.10* | 0.11* | 0.12* | 0.11* | 0.14* | 0.14* | 0.24* | 0.25* | 0.25* | 0.26* | 0.09* | 0.08* |
| Free Cashflow | -100.0% | - | 2,267 | 2,036 | 2,015 | 2,067 | 2,453 | 2,738 | 3,016 | 2,973 | 2,712 | 2,790 | 2,254 | 1,960 | 1,798 | 1,542 | 1,898 | 1,910 | 2,053 | 2,038 | 1,639 | 1,098 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 1.6% | 37,409 | 36,830 | 36,884 | 35,983 | 36,032 | 36,137 | 34,631 | 34,145 | 33,698 | 33,455 | 34,330 | 32,286 | 31,483 | 29,440 | 30,167 | 26,659 | 26,354 | 25,937 | 27,229 | 22,084 | 21,570 |
| Current Assets | 0.0% | 10,151 | 10,155 | 10,275 | 9,318 | 8,825 | 8,725 | 10,017 | 9,460 | 9,032 | 8,979 | 9,707 | 13,545 | 12,801 | 10,736 | 11,058 | 8,566 | 8,185 | 7,888 | 9,733 | 7,918 | 7,413 |
| Cash Equivalents | -16.2% | 1,401 | 1,671 | 1,844 | 1,420 | 1,044 | 1,458 | 2,944 | 2,563 | 2,241 | 2,238 | 2,943 | 7,083 | 6,539 | 3,964 | 4,337 | 1,948 | 1,754 | 1,674 | 3,616 | 1,918 | 1,641 |
| Inventory | 6.0% | 4,593 | 4,333 | 3,995 | 3,883 | 3,749 | 3,525 | 3,314 | 3,434 | 3,431 | 3,473 | 3,494 | 3,459 | 3,442 | 3,359 | 2,980 | 3,269 | 3,198 | 3,064 | 2,955 | 2,893 | 2,740 |
| Net PPE | 1.5% | 3,082 | 3,037 | 2,970 | 2,798 | 2,803 | 2,793 | 2,833 | 2,746 | 2,738 | 2,710 | 2,752 | 2,529 | 2,527 | 2,607 | 2,567 | 2,460 | 2,387 | 2,297 | 2,291 | 2,178 | 2,101 |
| Goodwill | 2.2% | 15,172 | 14,849 | 14,880 | 14,993 | 15,115 | 15,228 | 12,918 | 12,893 | 12,802 | 12,803 | 12,778 | 9,128 | 9,074 | 9,025 | 9,069 | 8,704 | 8,762 | 114 | 8,563 | 7,634 | 7,636 |
| Liabilities | 0.6% | 20,048 | 19,935 | 20,268 | 19,520 | 20,358 | 21,091 | 19,754 | 19,967 | 19,878 | 19,953 | 21,246 | 19,300 | 18,729 | 16,325 | 17,360 | 14,344 | 14,411 | 14,244 | 15,499 | 12,224 | 12,110 |
| Current Liabilities | 12.2% | 6,584 | 5,866 | 6,303 | 4,571 | 4,404 | 4,408 | 4,549 | 4,449 | 4,252 | 3,953 | 5,041 | 4,689 | 4,405 | 4,162 | 4,400 | 3,921 | 3,946 | 3,713 | 4,807 | 4,153 | 4,046 |
| LT Debt, Non Current | -6.0% | 11,149 | 11,857 | 11,857 | 12,751 | 13,374 | 13,885 | 12,472 | 12,629 | 12,734 | 13,059 | 13,230 | 12,008 | 11,811 | 9,404 | 10,231 | 7,889 | 7,974 | 7,950 | 8,486 | 5,928 | 5,925 |
| Shareholder's Equity | 2.8% | 17,361 | 16,895 | 16,616 | 16,463 | 15,674 | 15,046 | 14,877 | 14,178 | 13,820 | 13,502 | 13,084 | 12,986 | 12,754 | 13,115 | 12,807 | 12,315 | 11,943 | 11,693 | 11,730 | 9,860 | 9,460 |
| Retained Earnings | 3.0% | 15,526 | 15,072 | 14,765 | 14,486 | 13,933 | 13,540 | 13,480 | 13,081 | 12,881 | 12,525 | 12,462 | 12,129 | 11,725 | 12,024 | 11,748 | 11,238 | 10,967 | 10,683 | 10,765 | 8,892 | 8,477 |
| Additional Paid-In Capital | 1.8% | 2,127 | 2,090 | 2,034 | 2,028 | 1,989 | 1,947 | 1,890 | 1,875 | 1,844 | 1,806 | 1,741 | 1,736 | 1,706 | 1,676 | 1,628 | 1,593 | 1,569 | 1,538 | 1,559 | 1,535 | 1,503 |
| Accumulated Depreciation | 2.5% | 3,005 | 2,933 | 2,835 | 2,736 | 2,746 | 2,739 | 2,665 | 2,694 | 2,624 | 2,496 | 2,430 | 2,310 | 2,248 | 2,169 | 2,147 | 2,143 | 2,091 | 2,045 | 1,986 | 1,974 | 1,935 |
| Shares Outstanding | 0.2% | 380 | 379 | - | 378 | 378 | 378 | - | 377 | 377 | 376 | - | 376 | 376 | 375 | - | 374 | 374 | 373 | - | 374 | 374 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 5.5% | 3,025 | 2,866 | 2,624 | 2,621 | 2,665 | 3,014 | 3,263 | 3,500 | 3,396 | 3,138 | 3,277 | 2,775 | 2,575 | 2,469 | 2,191 | 2,502 | 2,491 | 2,626 | 2,610 | 2,243 | 1,704 |
| Share Based Compensation | 1.8% | 174 | 171 | 168 | 170 | 171 | 174 | 171 | 168 | 163 | 154 | 142 | 147 | 150 | 148 | 127 | 127 | 125 | 125 | 119 | 115 | 112 |
| Cashflow From Investing | -101.9% | -755 | -374 | -2,924 | -3,076 | -3,395 | -3,445 | -859 | -4,897 | -4,719 | -4,634 | -4,701 | -1,068 | -1,185 | -1,315 | -1,455 | -2,364 | -2,334 | -2,311 | -2,857 | -1,689 | -2,348 |
| Cashflow From Financing | 15.7% | -1,875 | -2,223 | -749 | -591 | -396 | -319 | -2,365 | -3,134 | -3,028 | -296 | -11.00 | 3,409 | 3,426 | 1,182 | 3.00 | -80.00 | -34.00 | -763 | 1,329 | -1,223 | -1,389 |
| Dividend Payments | 2.1% | 1,095 | 1,073 | 1,051 | 1,025 | 1,000 | 974 | 950 | 929 | 907 | 886 | 863 | 840 | 819 | 798 | 778 | 760 | 741 | 722 | 703 | 687 | 670 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 307 | 307 | 307 | 307 | 300 | 300 | 300 |
SYK Income Statement
2023-06-30CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net sales | $ 4,996 | $ 4,493 | $ 9,774 | $ 8,768 |
| Cost of sales | 1,815 | 1,667 | 3,577 | 3,208 |
| Gross profit | 3,181 | 2,826 | 6,197 | 5,560 |
| Research, development and engineering expenses | 346 | 351 | 685 | 764 |
| Selling, general and administrative expenses | 1,706 | 1,539 | 3,487 | 3,249 |
| Recall charges, net | 3 | 4 | 3 | 18 |
| Amortization of intangible assets | 161 | 160 | 322 | 310 |
| Total operating expenses | 2,216 | 2,054 | 4,497 | 4,341 |
| Operating income | 965 | 772 | 1,700 | 1,219 |
| Other income (expense), net | (66) | (52) | (122) | (113) |
| Earnings before income taxes | 899 | 720 | 1,578 | 1,106 |
| Income taxes | 161 | 64 | 248 | 127 |
| Net earnings | $ 738 | $ 656 | $ 1,330 | $ 979 |
| Net earnings per share of common stock: | ||||
| Basic (in dollars per share) | $ 1.95 | $ 1.73 | $ 3.51 | $ 2.59 |
| Diluted (in dollars per share) | $ 1.93 | $ 1.72 | $ 3.47 | $ 2.56 |
| Weighted-average shares outstanding (in millions): | ||||
| Basic (in shares) | 379.7 | 378.3 | 379.4 | 378.0 |
| Effect of dilutive employee stock compensation (in shares) | 4.2 | 3.9 | 4.2 | 4.5 |
| Diluted (in shares) | 383.9 | 382.2 | 383.6 | 382.5 |
| Cash dividends declared per share of common stock (in dollars per share) | $ 0.75 | $ 0.695 | $ 1.50 | $ 1.39 |
SYK Balance Sheet
2023-06-30CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 1,401 | $ 1,844 |
| Marketable securities | 77 | 84 |
| Accounts receivable, less allowance of $181 ($154 in 2022) | 3,261 | 3,565 |
| Inventories: | ||
| Materials and supplies | 1,221 | 1,006 |
| Work in process | 391 | 348 |
| Finished goods | 2,981 | 2,641 |
| Total inventories | 4,593 | 3,995 |
| Prepaid expenses and other current assets | 819 | 787 |
| Total current assets | 10,151 | 10,275 |
| Property, plant and equipment: | ||
| Land, buildings and improvements | 1,646 | 1,739 |
| Machinery and equipment | 4,441 | 4,066 |
| Total property, plant and equipment | 6,087 | 5,805 |
| Less allowance for depreciation | 3,005 | 2,835 |
| Property, plant and equipment, net | 3,082 | 2,970 |
| Goodwill | 15,172 | 14,880 |
| Other intangibles, net | 4,917 | 4,885 |
| Noncurrent deferred income tax assets | 1,439 | 1,410 |
| Other noncurrent assets | 2,648 | 2,464 |
| Total assets | 37,409 | 36,884 |
| Current liabilities | ||
| Accounts payable | 1,326 | 1,413 |
| Accrued compensation | 929 | 1,149 |
| Income taxes | 298 | 292 |
| Dividends payable | 284 | 284 |
| Accrued product liabilities | 220 | 230 |
| Accrued expenses and other liabilities | 1,729 | 1,744 |
| Current maturities of debt | 1,798 | 1,191 |
| Total current liabilities | 6,584 | 6,303 |
| Long-term debt, excluding current maturities | 11,149 | 11,857 |
| Income taxes | 469 | 641 |
| Other noncurrent liabilities | 1,846 | 1,467 |
| Total liabilities | 20,048 | 20,268 |
| Shareholders' equity | ||
| Common stock, $0.10 par value | 38 | 38 |
| Additional paid-in capital | 2,127 | 2,034 |
| Retained earnings | 15,526 | 14,765 |
| Accumulated other comprehensive loss | (330) | (221) |
| Total shareholders' equity | 17,361 | 16,616 |
| Total liabilities and shareholders' equity | $ 37,409 | $ 36,884 |
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.